Search for other papers by Aida Javanbakht in
Google Scholar
PubMed
Search for other papers by Massimo D’Apuzzo in
Google Scholar
PubMed
Search for other papers by Behnam Badie in
Google Scholar
PubMed
Search for other papers by Behrouz Salehian in
Google Scholar
PubMed
panhypopituitarism (3 cases) and DI (3 cases). Visual symptoms were also noted in two patients. In keeping with the natural history of these lesions, several patients did not have any pituitary-related clinical manifestations. Four patients underwent transsphenoidal
Search for other papers by L M Mongioì in
Google Scholar
PubMed
Search for other papers by R A Condorelli in
Google Scholar
PubMed
Search for other papers by S La Vignera in
Google Scholar
PubMed
Search for other papers by A E Calogero in
Google Scholar
PubMed
Objective
Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic strategy as it contemplates a once-daily tablet that allows more closely mimicking the physiological circadian cortisol rhythm. The aim of the study was to evaluate the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with AI.
Design and Methods
In this clinical open trial, we enrolled ten patients with primary AI (41 ± 2.67 years) and nine patients with AI secondary to hypopituitarism (53.2 ± 17.7 years). We evaluated the glycometabolic profile before and 3, 6, 9 and 12 months after dual-release hydrocortisone administration. We also evaluated health-related quality of life, estimated by the AddiQol questionnaire. The mean dose administered of dual-release hydrocortisone was 28.33 ± 6.68 mg/day.
Results
One female hypopituitary patient dropped out from the study. After 12 months of treatment, the mean dosage administered of dual-release hydrocortisone was significantly lower (P < 0.05) and all patients reported improved quality of life and well-being. The glycometabolic profile improved and the glycosylated hemoglobin decreased significantly in patients with primary AI (6.25 ± 0.2 vs 5.35 ± 0.17, P < 0.05). In contrast, hypopituitary patients had worse glycometabolic profile and a trend toward hypertriglyceridemia.
Conclusions
Dual-release hydrocortisone treatment improved the quality of life of patients with AI, and it allowed a decrease of cortisol dosage administered in the absence of side effects. The glycometabolic profile worsened in hypopituitary patients.
Search for other papers by Ruth Percik in
Google Scholar
PubMed
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Search for other papers by Safwaan Adam in
Google Scholar
PubMed
Search for other papers by Kate Young in
Google Scholar
PubMed
Royal Marsden Hospital, London, UK
Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed
. Hypothalamic–pituitary–adrenal (HPA) axis Hypophysitis and hypopituitarism Pituitary abnormalities are reported in between 1.8 and 18.3% of patients treated with ipilimumab-based regimens ( 17 ), usually resulting in panhypopituitarism, associated with
Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by J Van Schaik in
Google Scholar
PubMed
Department of Exercise Physiology, Child Development & Exercise Center, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by M Burghard in
Google Scholar
PubMed
Department of Radiology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by M H Lequin in
Google Scholar
PubMed
Department of Radiology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by E A van Maren in
Google Scholar
PubMed
Search for other papers by A M van Dijk in
Google Scholar
PubMed
Department of Exercise Physiology, Child Development & Exercise Center, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by T Takken in
Google Scholar
PubMed
Search for other papers by L B Rehorst-Kleinlugtenbelt in
Google Scholar
PubMed
Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by B Bakker in
Google Scholar
PubMed
Search for other papers by L Meijer in
Google Scholar
PubMed
Search for other papers by E W Hoving in
Google Scholar
PubMed
Institute of Mathematics, Leiden University, Leiden, The Netherlands
Search for other papers by M Fiocco in
Google Scholar
PubMed
Search for other papers by A Y N Schouten-van Meeteren in
Google Scholar
PubMed
Division of Pediatric Oncology, University Medical Centre Groningen, Groningen, The Netherlands
Search for other papers by W J E Tissing in
Google Scholar
PubMed
Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by H M van Santen in
Google Scholar
PubMed
pituitary dysfunction and/or diabetes insipidus (DI)), grade II (panhypopituitarism with DI), and grade III (panhypopituitarism with DI and impaired thirst regulation) ( 46 ). Neuroimaging On the brain MRI performed at time of diagnosis, the
Search for other papers by I M A A van Roessel in
Google Scholar
PubMed
Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
Endo-ERN European Reference Network on Rare endocrine conditions
Search for other papers by J P de Graaf in
Google Scholar
PubMed
Endo-ERN European Reference Network on Rare endocrine conditions
Search for other papers by N R Biermasz in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
Search for other papers by E Charmandari in
Google Scholar
PubMed
Search for other papers by H M van Santen in
Google Scholar
PubMed
). Unfortunately, there is no effective treatment for all aspects of HD, and HD may not be the same for every individual; some patients will experience obesity, sleep problems and panhypopituitarism while others may be more disturbed by hypothermia and DI with
Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Search for other papers by Swati Ramteke-Jadhav in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Virendra Patil in
Google Scholar
PubMed
Search for other papers by Puja Thadani in
Google Scholar
PubMed
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Search for other papers by Atul Goel in
Google Scholar
PubMed
Search for other papers by Sridhar Epari in
Google Scholar
PubMed
Search for other papers by Naina Goel in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
.72/0.52 – <0.2 1.44 2.8/2.1 NA sterile abscess TSS DI 12 months, No residue/recurrence, panhypopituitarism on replacement 2 35/M Headache, fever, weight loss 0.94/1.02 – 4.35 7.9 2.1/1.78 2.31 tubercular abscess ATT
Department of Health Sciences, University of Florence, Florence, Italy
Search for other papers by Alessandro Barbato in
Google Scholar
PubMed
Search for other papers by Giulia Gori in
Google Scholar
PubMed
Search for other papers by Michele Sacchini in
Google Scholar
PubMed
Search for other papers by Francesca Pochiero in
Google Scholar
PubMed
Search for other papers by Sara Bargiacchi in
Google Scholar
PubMed
Search for other papers by Giovanna Traficante in
Google Scholar
PubMed
Search for other papers by Viviana Palazzo in
Google Scholar
PubMed
Search for other papers by Lucia Tiberi in
Google Scholar
PubMed
Search for other papers by Claudia Bianchini in
Google Scholar
PubMed
Search for other papers by Davide Mei in
Google Scholar
PubMed
Search for other papers by Elena Parrini in
Google Scholar
PubMed
Search for other papers by Tiziana Pisano in
Google Scholar
PubMed
Search for other papers by Elena Procopio in
Google Scholar
PubMed
NEUROFARBA Department, University of Florence, Florence, Italy
Search for other papers by Renzo Guerrini in
Google Scholar
PubMed
Department of Clinical and Experimental Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy
Search for other papers by Angela Peron in
Google Scholar
PubMed
Department of Health Sciences, University of Florence, Florence, Italy
Search for other papers by Stefano Stagi in
Google Scholar
PubMed
unrelated patient with progressive panhypopituitarism and DEE in whom we identified homozygous missense SCO1 mutations. To our knowledge, DEE and pituitary involvement have not yet been associated with MC4DN4. Subjects and methods We conducted a
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Search for other papers by G Giuffrida in
Google Scholar
PubMed
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by F Ferraù in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by R Laudicella in
Google Scholar
PubMed
Search for other papers by O R Cotta in
Google Scholar
PubMed
Search for other papers by E Messina in
Google Scholar
PubMed
Neuroradiology Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F Granata in
Google Scholar
PubMed
Neurosurgery Unit of University Hospital ‘AOU Policlinico G. Martino’, Messina, Italy
Search for other papers by F F Angileri in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by A Vento in
Google Scholar
PubMed
Search for other papers by A Alibrandi in
Google Scholar
PubMed
Department of Biomorphology, University of Messina, Messina, Sicily, Italy
Search for other papers by S Baldari in
Google Scholar
PubMed
PhD School of Clinical and Experimental Biomedical Sciences, University of Messina, Messina, Sicily, Italy
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Sicily, Italy
Search for other papers by S Cannavò in
Google Scholar
PubMed
. Panhypopituitarism had occurred after radiosurgery. In 2015, he began PRRT but a dramatic increase in tumor size (from 20.2 to 83.6 mL), impairment of visual acuity and worsening of clinical conditions occurred after the second cycle of treatment. For this reason
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
growth hormone and gonadotropins in a woman with panhypopituitarism: a new treatment protocol . Fertility and Sterility 2000 74 1248 – 1250 . ( https://doi.org/10.1016/s0015-0282(0001619-8 ) 19 Müller J Starup J Christiansen JS Jørgensen JO
Search for other papers by Lingjuan Li in
Google Scholar
PubMed
Search for other papers by Jing Qin in
Google Scholar
PubMed
Search for other papers by Lin Ren in
Google Scholar
PubMed
Search for other papers by Shiyuan Xiang in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Medical Brain Function and Restoration and Neural Regeneration, Fudan University, Shanghai, China
Search for other papers by Xiaoyun Cao in
Google Scholar
PubMed
Search for other papers by Xianglan Zheng in
Google Scholar
PubMed
Search for other papers by Zhiwen Yin in
Google Scholar
PubMed
National Center for Neurological Disorders, Shanghai, China
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
Neurosurgical Institute of Fudan University, Shanghai, China
Shanghai Key Laboratory of Medical Brain Function and Restoration and Neural Regeneration, Fudan University, Shanghai, China
Search for other papers by Nidan Qiao in
Google Scholar
PubMed
a patient with panhypopituitarism after short-term discontinuation of desmopressin . Israel Medical Association Journal 2020 22 330 – 332 . 6 Qiao N . A systematic review on machine learning in sellar region diseases: quality and reporting